A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2012
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2012 Actual patient number (13) added as reported by ClinicalTrials.gov record.
- 27 Feb 2012 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov record.